Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP946947.RAbfTfdHBwhbJKlh58dF7NNQrs5RkSeuCHjU9mJr9LcEE130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP946947.RAbfTfdHBwhbJKlh58dF7NNQrs5RkSeuCHjU9mJr9LcEE130_assertion type Assertion NP946947.RAbfTfdHBwhbJKlh58dF7NNQrs5RkSeuCHjU9mJr9LcEE130_head.
- NP946947.RAbfTfdHBwhbJKlh58dF7NNQrs5RkSeuCHjU9mJr9LcEE130_assertion description "[Herein, we report the response to treatment with a fixed dosing schedule of ME or MEC in 65 patients treated for primary refractory or relapsed AML with intermediate or unfavorable risk cytogenetics.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP946947.RAbfTfdHBwhbJKlh58dF7NNQrs5RkSeuCHjU9mJr9LcEE130_provenance.
- NP946947.RAbfTfdHBwhbJKlh58dF7NNQrs5RkSeuCHjU9mJr9LcEE130_assertion evidence source_evidence_literature NP946947.RAbfTfdHBwhbJKlh58dF7NNQrs5RkSeuCHjU9mJr9LcEE130_provenance.
- NP946947.RAbfTfdHBwhbJKlh58dF7NNQrs5RkSeuCHjU9mJr9LcEE130_assertion SIO_000772 22172465 NP946947.RAbfTfdHBwhbJKlh58dF7NNQrs5RkSeuCHjU9mJr9LcEE130_provenance.
- NP946947.RAbfTfdHBwhbJKlh58dF7NNQrs5RkSeuCHjU9mJr9LcEE130_assertion wasDerivedFrom befree-2016 NP946947.RAbfTfdHBwhbJKlh58dF7NNQrs5RkSeuCHjU9mJr9LcEE130_provenance.
- NP946947.RAbfTfdHBwhbJKlh58dF7NNQrs5RkSeuCHjU9mJr9LcEE130_assertion wasGeneratedBy ECO_0000203 NP946947.RAbfTfdHBwhbJKlh58dF7NNQrs5RkSeuCHjU9mJr9LcEE130_provenance.